MedPath

Study to Evaluate Clinical Efficacy and Safety of "Medifoam H" in Wound Healing

Phase 4
Completed
Conditions
Trauma
Interventions
Device: Medifoam H dressing
Device: Duoderm THIN dressing
Registration Number
NCT01548443
Lead Sponsor
Seoul St. Mary's Hospital
Brief Summary

The wound healing efficacy and safety of "Medifoam H" in patients with minor, acute trauma.

The hypothesis of this study is that using "Medifoam H" dressing for a week is not inferior to using "Duoderm THIN" dressing in wound healing.

Detailed Description

This study is single-center, randomized, active-controlled, open-label, Phase IV to evaluate clinical efficacy of wound healing and safety of "Medifoam H" in patients with minor, acute trauma.

33 patients of treatment group and 33 patients of control group, total 66 patients will be enrolled to this study. Every patient will be treated with "Medifoam H" or "Duoderm THIN" for a week. During their participation, patients will visit 2 days and a week after to see investigator. Investigator will observe the wound and evaluate amount of exudation, infection status, wound healing.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
66
Inclusion Criteria
  1. Who has acute trauma(Laceration, Abrasion, Stitched wound, under superficial second-degree burn etc.)who satisfies at least 1 condition between followings:

  2. Laceration, Stitched Wound: Length of under 10cm.

  3. Abrasion, Burn: Total area of under 100㎠ , Depth of under 2mm. 2. Agreed to participate voluntarily in the study

Exclusion Criteria
  1. Who has hypersensitivity to hydrocolloid or its history.
  2. Deep or severe infectious diseases of skin(example: Phlegmon, Abscess, Ulcer, Boil etc..) which is hard to treat with this investigational product.
  3. A wound which is bitten by animal, human or inject. Or a wound has possibility of secondary infection through the tresis.
  4. Who need surgical intervention for infection treatment.
  5. Who has bacterial, viral, animal infectious disease
  6. Who judged inappropriate to participate in the study by investigator.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Medifoam HMedifoam H dressingA group which treated with "medifoam H" on the wound.
Duoderm THINDuoderm THIN dressingA group which treated with " Duoderm THIN " on the wound
Primary Outcome Measures
NameTimeMethod
Wound healing rate according to amount of exudation at 1 week from baseline. If exudation is not existed, this will be defined as recovery0 to 1 week

Wound healing rate according to amount of exudation at 1 week from baseline. If exudation is not existed, this will be defined as recovery. Exudation will be scored in 4 level: None/Mild/Normal/Severe.

Secondary Outcome Measures
NameTimeMethod
Rate of infection on wound1/3/7 days.

Rate of infection on wound. Infection means pus, erythema or tenderness and this will be judged by observation of investigator and scored in 3 level: not present/minimally present/extensively present.

Amount of exudation at day 3.3 days

Amount of exudation at day 3 from baseline. If exudation is not existed, this will be defined as recovery. Exudation will be scored in 4 level: None/Mild/Normal/Severe

Rate of wound healing3/7 days

Rate of wound healing at day 3 and 7 from baseline. Would healing will be scored in 3 level: Better/Same/Worse.

Rate of changes in tissue after treatment3/7 days

Rate of changes in tissue after treatment at day 3 and 7 from baseline. Changes in tissue will be recorded as percentage. Necrotic, sloughy, fibrous, granulation, epithelial, other tissues will be observed

Whether use of concomitant medication or not1/3/7 days

Whether use of concomitant medication or not

Trial Locations

Locations (1)

Seoul St. Mary's Hospital

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath